{
    "clinical_study": {
        "@rank": "30198", 
        "arm_group": [
            {
                "arm_group_label": "HCP1201", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2)."
            }, 
            {
                "arm_group_label": "Metformin and Rosuvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2)."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the pharmacokinetic characteristics between HCP1201 tablet 750/10 mg and\n      co-administration of metformin 750 mg plus rosuvastatin 10 mg under fed state condition."
        }, 
        "brief_title": "Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After\n      the Administration of HCP1201 Tablet 750/10 mg and Coadministration of Metformin SR 750 mg\n      and Rosuvastatin 10 mg in Healthy Volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteer, age 20~55 years\n\n          -  The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2\n\n          -  Subject who has the ability to comprehend the study objectives, contents and the\n             property of the study drug before participating in the trial.\n\n        Exclusion Criteria:\n\n          -  Presence of medical history or a concurrent disease that may interfere with treatment\n             and safety assessment or completion of this clinical study\n\n          -  History of relevant drug allergies or clinically significant hypersensitivity\n             reaction."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026817", 
            "org_study_id": "HM-MERO-104"
        }, 
        "intervention": [
            {
                "arm_group_label": "HCP1201", 
                "description": "750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.", 
                "intervention_name": "HCP1201 750/10mg", 
                "intervention_type": "Drug", 
                "other_name": "HCP1201 750/10mg"
            }, 
            {
                "arm_group_label": "Metformin and Rosuvastatin", 
                "description": "Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.", 
                "intervention_name": "Metformin SR 750mg", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage SR 750 mg"
            }, 
            {
                "arm_group_label": "Metformin and Rosuvastatin", 
                "description": "Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.", 
                "intervention_name": "Rosuvastatin 10mg", 
                "intervention_type": "Drug", 
                "other_name": "Crestor 10mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 750/10 mg and Coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Jung-Ryul Kim, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "metformin, rosuvastatin Cmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }, 
            {
                "measure": "metformin, rosuvastatin AUClast", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026817"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Metformin, rosuvastatin Tmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }, 
            {
                "measure": "Metformin, rosuvastatin T1/2", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }, 
            {
                "measure": "Metformin, rosuvastatin AUCinf", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}